var data={"title":"Factor VIII, recombinant human pegylated: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Factor VIII, recombinant human pegylated: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/791351?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=factor-viii-recombinant-human-pegylated-patient-drug-information\" class=\"drug drug_patient\">see &quot;Factor VIII, recombinant human pegylated: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45755753\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Adynovate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50755713\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Adynovate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45650205\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihemophilic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760119\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemophilia A:</b> IV: Dose, dosing frequency, and duration based on location and severity of bleeding, target factor VIII levels, and clinical condition of the patient. Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Treatment and control of bleeding episodes:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Dosage based on desired factor VIII increase (%):</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">To calculate dosage needed based on desired factor VIII increase (%):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">[Body weight (kg) x desired factor VIII increase (%)] divided by 2(%/units/kg) = units factor VIII required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>For example:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">50 kg x 30 (% increase) divided by 2 = 750 units factor VIII</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Dosage based on expected factor VIII increase (%):</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">It is also possible to calculate the <b>expected</b> % factor VIII increase:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">[# units administered x 2(%/units/kg)] divided by body weight (kg) = expected % factor VIII increase</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>For example:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">[1,400 units x 2] divided by 70 kg = 40%</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">General Antihemophilic Factor Dosing for On-demand Treatment and Control of Bleeding Episodes</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th valign=\"bottom\" align=\"center\">\n            <p style=\"text-indent:0em;\">Type of Bleeding</p></th>\n          <th valign=\"bottom\" align=\"center\">\n            <p style=\"text-indent:0em;\">Target Factor VIII Level (Units/dL or % of normal)</p></th>\n          <th valign=\"bottom\" align=\"center\">\n            <p style=\"text-indent:0em;\">Dose (Units/kg)</p></th>\n          <th valign=\"bottom\" align=\"center\">\n            <p style=\"text-indent:0em;\">Frequency of Dosing (hours)</p></th>\n          <th valign=\"bottom\" align=\"center\">\n            <p style=\"text-indent:0em;\">Duration of therapy</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"5\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <b>Note:</b> Factor VIII level may either be expressed as units/dL or as %. Dosing frequency most commonly corresponds to the half-life of factor VIII but should be determined based on an assessment of factor VIII levels before the next dose.</p></td></tr></tfoot>\n      <tbody>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Minor early hemarthrosis, mild muscle bleeding, or mild oral bleeding episode</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 to 40</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 to 20</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 to 24</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Until bleeding is resolved</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Moderate muscle bleeding, moderate bleeding into the oral cavity, definite hemarthroses, and known trauma.</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 to 60</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 30</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 to 24</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Until bleeding is resolved</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Major significant gastrointestinal bleeding, intracranial, intra-abdominal or intrathoracic bleeding, central nervous system bleeding, bleeding in the retropharyngeal or retroperitoneal spaces or iliopsoas sheath, fractures, head trauma.</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60 to 100</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 to 50</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 24</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Until bleeding is resolved</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Perioperative management</b>\n      <b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Minor (including tooth extraction):</b> Initial: 30 to 50 units/kg/dose beginning 1 hour before surgery to achieve factor VIII level of 60% to 100% of normal; repeat after 24 hours if necessary until bleeding is resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Major (intracranial, intra-abdominal, or intrathoracic surgery, joint replacement surgery):</b> Initial: 40 to 60 units/kg/dose beginning 1 hour before surgery to achieve factor VIII level of 80% to 120% of normal pre- and postoperatively. Verify 100% activity has been achieved prior to surgery. Maintenance: 40 to 60 units/kg/dose every 8 to 24 hours until adequate wound healing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Routine prophylaxis to reduce the frequency of bleeding episodes: </b> 40 to 50 units/kg/dose twice weekly; adjust dose based on clinical response.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760118\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hemophilia A:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Perioperative management:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 to &lt;12 years: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Minor (including tooth extraction):</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Major (intracranial, intra-abdominal, or intrathoracic surgery, joint replacement surgery):</b> Initial: 40 to 60 units/kg/dose beginning 1 hour before surgery to achieve factor VIII level of 80% to 120% of normal pre- and postoperatively. Verify 100% activity has been achieved prior to surgery. Maintenance: 40 to 60 units/kg/dose every 6 to 24 hours until adequate wound healing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment and control of bleeding episodes:</b> Children &ge;1 years and Adolescents: IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Routine prophylaxis to reduce the frequency of bleeding episodes:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 to &lt;12 years: IV: 55 units/kg/dose twice weekly (maximum dose: 70 units/kg/dose); adjust dose based on clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents: IV: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760120\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760121\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760122\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45755754\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adynovate: 250 units (1 ea); 500 units (1 ea); 750 units (1 ea); 1000 units (1 ea); 1500 units (1 ea); 2000 units (1 ea) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adynovate: 3000 units (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45755752\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50640544\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strengths expressed with approximate values. Consult individual vial labels for exact potency within each vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760125\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV:  Over 5 minutes or less (maximum infusion rate of 10 mL/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">According to the World Federation of Hemophilia (WFH), infuse by slow IV injection at a rate not to exceed 3 mL/minute (adults) or 100 <b>units</b>/minute (young children); may also administer as a continuous infusion in select patients (WFH [Srivastava 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45650193\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hemophilia A:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Perioperative management: </b>Surgical prophylaxis in adults and children with hemophilia A.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Treatment and control of bleeding episodes:</b> On-demand treatment and control of bleeding episodes in adults and children with hemophilia A.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Routine prophylaxis to reduce the frequency of bleeding: </b>Routine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia A.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Not indicated for the treatment of von Willebrand disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45692632\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: Central nervous system: Headache (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined: Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute pancreatitis, antibody development (neutralizing), diarrhea, flushing, hypersensitivity reaction, nausea, skin rash</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45650194\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Anaphylactic reaction to antihemophilic factor (recombinant/pegylated), antihemophilic factor (recombinant), mouse or hamster protein, or any component of the formulation (eg, Tris, mannitol, trehalose, glutathione, and/or polysorbate 80)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760110\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: Formation of antibodies (inhibitors) to factor VIII antibodies may occur; monitor patients for the development of antibodies by clinical observation and laboratory tests. Suspect factor VIII antibodies if the plasma factor VIII level does not increase as expected or if bleeding is not controlled after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: May occur; discontinue immediately if allergic or anaphylactic-type reactions occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mouse/hamster protein: May contain trace amounts of mouse or hamster protein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: May contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dose requirements: The dosage requirement will vary in patients with factor VIII inhibitors; optimal treatment should be determined by clinical response.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45730334\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45730331\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=105442&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Emicizumab-kxwh: May enhance the thrombogenic effect of Factor VIII Products.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760108\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Factor VIII concentrations may increase in pregnant women with coagulation disorders. Pregnant women should have clotting factors monitored, particularly at 28 and 34 weeks gestation and prior to invasive procedures. Prophylaxis may be needed if concentrations are &lt;50 units/mL at term and treatment should continue for 3 to 5 days postpartum depending on route of delivery. The neonate may also be at an increased risk of bleeding following delivery and should be tested for the coagulation disorder (Kadir 2009; Lee 2006). Although recombinant products are generally preferred when therapy in pregnancy is needed, initial studies conducted with the pegylated product were done only in males (Konkle 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760109\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if antihemophilic factor is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760124\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760128\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity reactions, heart rate and blood pressure (before and during IV administration); plasma factor VIII activity prior to and during treatment using a one-stage clotting assay to confirm adequate factor VIII levels have been achieved and maintained); development of factor VIII inhibitors using the Bethesda inhibitor assay; signs of bleeding; hemoglobin, hematocrit.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760127\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Classification of hemophilia; normal is defined as 1 unit/mL of factor VIII (WFH [Srivastava 2013]) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe: Factor level &lt;1% of normal </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate: Factor level 1% to 5% of normal </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild: Factor level &gt;5% to &lt;40% of normal </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760114\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Factor VIII replacement, necessary for clot formation and maintenance of hemostasis, activates factor X in conjunction with activated factor IX. Activated factor X converts prothrombin to thrombin, which converts fibrinogen to fibrin, and with factor XIII forms a stable clot.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45760116\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: Children &lt;6 years: 0.97 &plusmn; 0.23 dL/kg; Children 6 to &lt;12 years: 1.59 &plusmn; 0.34 dL/kg; Children and Adolescents 12 to &lt;18 years: 0.56 &plusmn; 0.18 dL/kg; Adults &ge;18 years: 0.43 &plusmn; 0.11 dL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Children &lt;6 years: 11.8 &plusmn; 2.43 hours; Children 6 to &lt;12 years: 12.4 &plusmn; 1.67 hours; Children and Adolescents 12 to &lt;18 years: 13.43 &plusmn; 4.05 hours; Adults &ge;18 years: 14.69 &plusmn; 3.79 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Children and Adolescents 12 to &lt;18 years: 0.26 &plusmn; 0.1 hours; Adults &ge;18 years: 0.46 &plusmn; 0.29 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49940051\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adynovate (JP)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adynovate (antihemophilic factor [recombinant (pegylated)]) [prescribing information]. Westlake Village, CA: Baxalta US Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adynovate (antihemophilic factor [recombinant (pegylated)]) [prescribing information]. Westlake Village, CA: Baxalta US Inc.; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. <i>Haemophilia</i>. 2009;15(5):990-1005. doi: 10.1111/j.1365-2516.2009.01984.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-drug-information/abstract-text/19298378/pubmed\" target=\"_blank\" id=\"19298378\">19298378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. <i>Blood</i>. 2015;126(9):1078-1085.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-drug-information/abstract-text/26157075/pubmed\" target=\"_blank\" id=\"26157075\">26157075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee CA, Chi C, Pavord SR; et al; UK Haemophilia Centre Doctors' Organization. The obstetric and gynaecological management of women with inherited bleeding disorders--review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization. <i>Haemophilia</i>. 2006;12(4):301-336.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-drug-information/abstract-text/16834731/pubmed\" target=\"_blank\" id=\"16834731\">16834731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Treatment Guidelines Working Group on behalf of the World Federation Of Hemophilia. Guidelines for the management of hemophilia. <i>Haemophilia</i>. 2013;19(1):e1-e47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-viii-recombinant-human-pegylated-drug-information/abstract-text/22776238/pubmed\" target=\"_blank\" id=\"22776238\">22776238</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 105442 Version 32.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45755753\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50755713\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F45650205\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F45760119\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F45760118\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F45760120\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F45760121\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F45760122\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45755754\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F45755752\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F50640544\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F45760125\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45650193\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45692632\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45650194\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45760110\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45730334\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45730331\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45760108\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F45760109\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F45760124\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45760128\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F45760127\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45760114\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F45760116\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49940051\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/105442|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=factor-viii-recombinant-human-pegylated-patient-drug-information\" class=\"drug drug_patient\">Factor VIII, recombinant human pegylated: Patient drug information</a></li></ul></div></div>","javascript":null}